Nyström A, Kiritopoulos D, Ullmark G, et al. - In this randomized, double-blind, placebo-controlled phase two trial involving 64 individuals (aged 35-65 years) with unilateral osteoarthritis of the hip, researchers ascertained if denosumab could inhibit early periprosthetic bone loss after total hip arthroplasty (THA) and assessed the impacts on periprosthetic [¹⁸F] standardized uptake values (SUVs). Participants in the study had surgery with an uncemented THA and were randomized to either two subcutaneous doses of denosumab (n = 32) or placebo (n = 32) given 1-3 days and 6 months after surgery. According to findings, denosumab effectively prevents early periprosthetic bone loss after uncemented THA, but the effect declines after treatment have been discontinued. More research is needed to decide whether this bone loss would prove clinically significant and, if so, whether either prolonged denosumab therapy or additional antiresorptive therapy can sustain the positive effect seen in this study.